XML 42 R18.htm IDEA: XBRL DOCUMENT v2.4.0.8
Segment Reporting
 3 Months Ended
Mar. 31, 2014
Segment Reporting [Abstract]  
Segment Reporting
Segment Reporting. The Company has four reportable segments: Apex, Oxford, Physician, and Life Sciences Europe. During the quarter ended March 31, 2014, the Company underwent a restructuring that realigned the former Life Sciences segment. As a result of this realignment, Lab Support U.S. is now included in the Apex segment; Valesta U.S. is now included in the Oxford segment; and the Life Sciences Europe segment includes Lab Support Europe, Valesta Europe, and Sharpstream. During 2013, the Company sold its Nurse Travel line of business and most of the Allied Healthcare line of business. See Note 4 Discontinued Operations for further information. The divestitures resulted in changes to the internal reporting package reviewed by the Chief Operating Decision Maker ("CODM"), and the Healthcare segment no longer exists. Health Information Management, formerly included in the Healthcare Segment, is included in the Oxford Segment and unallocated corporate expenses are separately disclosed in order to align with the revised internal reporting package reviewed by the CODM. All prior periods have been retrospectively restated to conform to the current presentation.

The Company’s management evaluates the performance of each segment primarily based on revenues, gross profit, and operating income. The information in the following table is derived directly from the segments’ internal financial reporting used for corporate management purposes. The Company's management does not evaluate, manage or measure performance of segments using asset information, and such information is not readily available. Accordingly, assets by reportable segment are not disclosed.

The following tables present revenues, gross profit, operating income and amortization by reportable segment for the three months ended March 31, 2014 and 2013 (in thousands):
2014:
Apex
 
Oxford
 
Physician
 
Life Sciences Europe
 
Corporate
 
Total
Revenues
$
278,408

 
$
117,500

 
$
31,791

 
$
11,575

 
$
—

 
$
439,274

Gross profit
75,506

 
49,026

 
8,838

 
4,218

 
—

 
137,588

Operating income
22,784

 
14,284

 
1,259

 
1,199

 
(12,244
)
 
27,282

Amortization
4,089

 
1,370

 
634

 
71

 
8

 
6,172


2013:
Apex
 
Oxford
 
Physician
 
Life Sciences Europe
 
Corporate
 
Total
Revenues
$
239,765

 
$
102,688

 
$
26,302

 
$
10,289

 
$
—

 
$
379,044

Gross profit
63,981

 
34,815

 
7,483

 
3,832

 
—

 
110,111

Operating income
17,229

 
13,666

 
2,426

 
533

 
(10,999
)
 
22,855

Amortization
4,881

 
107

 
176

 
160

 
55

 
5,379


The Company operates internationally, with operations mainly in the United States, Europe, Canada, Australia and New Zealand. The following table presents domestic and foreign revenues (in thousands):
 
Three Months Ended
 
March 31,
 
2014
 
2013
Revenues:
 
 
 
Domestic
$
418,664

 
$
358,648

Foreign
20,610

 
20,396

 
$
439,274

 
$
379,044